(San Francisco) -- Mytrus, an innovative clinical technology and services company for medical and pharmaceutical research, today announced that Anthony J. Costello has been appointed company CEO, effective immediately. He replaces Steve Cummings, MD, who is now the company's new chief scientific officer and who will remain as chairman of the board of directors.
"Mytrus is experiencing significant growth through the addition of new sponsors, partners and a greater number of ongoing clinical studies," Cummings said. "Going forward, I will be concentrating on the more scientific aspects of our business and ensuring that Mytrus achieves its mission: to enable people to safely participate in clinical trials from the convenience of their homes or in the field. Anthony will be responsible for the business aspects related to Mytrus as we broaden our customer base and product line for conducting direct-to-patient data clinical studies."
Costello is one of the founding members of Mytrus and previously served as its chief operating officer. Before joining the company in 2009, he co-founded Nextrials, Inc. and served as its vice president of product development; he also served for several years as manager of oncology clinical data management at Genentech, Inc. He is a past chairman of the board of trustees for the Society of Clinical Data Management and a member of the editorial advisory board for Applied Clinical Trials magazine. He holds a degree in sociology from the University of California at Berkeley.
The recipient of numerous awards, Cummings is recognized as an expert in the methodology for conducting clinical research. He is an elected member of the Institute of Medicine in the National Academy of Science, and is known for his leadership and studies in the areas of osteoporosis and aging. He is an emeritus Professor of Medicine and Epidemiology from the University of California, San Francisco and is a director of the San Francisco Coordinating Center.
Founded in 2009, Mytrus is a privately held e-clinical technology company specializing in patient-centered electronic informed consent and data collection tools. After receiving the first FDA approvals for remote electronic consent and virtual data collection, Mytrus has gone on to develop new technologies for patients including ePRO and EDC tools usable from home and mobile devices, bio-sample consent tracking technology, site training and e-learning applications, and patient home dashboards for tracking clinical study progress and data. Mytrus also holds an exclusive patent for conducting virtual clinical trials in the US. Mytrus investors include BioClinica and inVentiv Health.